MyMD Pharmaceuticals, Inc.
MYMD
$-0.01
Change (1 day)
$63.90
Year High
$1.75
Year Low
Categories
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
MyMD Pharmaceuticals, Inc. (MYMD) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -2,632,140 | 5.09 M | 17.86 M | 5.82 M | |
| 2022 | -607,369 | 2.84 M | 17.54 M | 5.4 M | |
| 2021 | -406,816 | 1.17 M | 24.81 M | 12.67 M | |
| 2020 | 3.98 M | 5.93 M | 676.7 K | 149.5 K | |
| 2019 | 42.88 K | 487.49 K | 1.53 M | 10.88 M | 10.31 M |